Latest Car T News

The Star Entertainment Group reported a 5% revenue increase in Q1 FY26 and a halving of its EBITDA loss, while navigating regulatory challenges and advancing a major joint venture exit.

CAR Group Limited has reported robust FY25 financial results with strong revenue and profit growth, underpinned by strategic investments in AI and digital marketplaces. The company projects continued momentum into FY26, aiming to deepen market leadership across global regions.

Harmoney has reaffirmed its FY26 profit guidance, aiming for a $12 million cash NPAT, while unveiling a new secured auto loan product designed to disrupt the car finance market.

Harmoney Corp Limited has reaffirmed its FY26 profit guidance of $12 million Cash NPAT, driven by strong loan book growth and the launch of a secured vehicle loan product leveraging its Stellare 2.0 platform.

Arovella Therapeutics reported solid progress in Q1 FY26, moving closer to initiating its first-in-human trial for ALA-101 while securing key patents and maintaining a strong cash position.

Peter Warren Automotive reports a strong FY25 with underlying profit before tax of $22.3 million, driven by disciplined inventory and cost management. The company declares a 4 cent fully franked dividend and signals confidence in growth through innovation and acquisitions.

Jumbo Interactive has completed its strategic entry into the US prize draw market by acquiring Dream Giveaway for A$55.4 million, aiming to leverage its digital expertise to fuel growth in a large, underpenetrated market.

INOVIQ Limited has raised $9.5 million to advance its pioneering ovarian cancer screening test and CAR-exosome therapeutic programs, backed by strong preclinical data and strategic partnerships.

AdAlta Limited has completed the final share issuance under its Investment Agreement with the Meurs Group, securing the full $700,000 investment that bolstered its cellular immunotherapy development.

AdAlta Limited has made significant progress in its 'East to West' cellular immunotherapy strategy, advancing licensing negotiations for its first CAR-T product and raising $1.6 million through placements to bolster its financial position.

Arovella Therapeutics has secured encouraging feedback from the US FDA on reagent testing for its CAR-iNKT cell therapy, setting the stage for an IND filing this quarter and clinical trials in early 2026.

Credit Corp Group has reaffirmed its FY26 guidance, highlighting robust earnings growth driven by operational improvements across its US debt buying and Australian/New Zealand lending segments.